• Source: ADB-BINACA

ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB1 receptor with a binding affinity (Ki) of 0.33 nM and an EC50 of 14.7 nM.




ADB-BUTINACA


The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound. It is a similarly potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC50 of 6.36 nM for CB1.




See also


4F-ADB
5F-AB-PINACA
5F-ADB
5F-ADB-PINACA
ADB-CHMINACA
ADB-FUBICA
ADB-FUBINACA
ADB-HEXINACA
ADB-PINACA
ADB-4en-PINACA




References

Kata Kunci Pencarian:

• ADB-BINACA
• ADB-BUTINACA
• MDMB-BINACA
• 5F-ADB
• ADB-FUBINACA
• 4F-MDMB-BINACA
• MDMB-4en-PINACA
• ADB-4en-PINACA
• ADB-5'Br-BUTINACA
• Cannabis (drug)